CB

CBRE Group IncNYSE CBRE Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

36.211

Large

Exchange

XNYS - New York Stock Exchange, Inc

CBRE Stock Analysis

CB

Avoid

Based on Eyestock quantitative analysis, CBRE`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

38/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-51.0 %

Greatly overvalued

Market cap $B

36.211

Dividend yield

Shares outstanding

309.89 B

CBRE Group, Inc. engages in the provision of commercial real estate and investment services. The company is headquartered in Dallas, Texas and currently employs 115,000 full-time employees. The company went IPO on 2004-06-10. The firm provides services to real estate investors and occupiers. The firm's Advisory Services segment provides a range of services globally, including property leasing, property sales, mortgage services, property management services and valuation services. The Global Workplace Solutions segment provides a suite of integrated, contractually based outsourcing services to occupiers of real estate, including facilities management and project management. The Real Estate Investments includes segment investment management services provided globally, development services in the United States, United Kingdom and Continental Europe. The Company’s services include capital markets, property leasing, investment management, project management services, property management, facilities management services and development services, among others. The company also provides expert technical support services for high-end laboratory systems in the United States.

View Section: Eyestock Rating